Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

Add BLRX Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017, BooDog
Search This Board: 
Last Post: 3/6/2018 2:13:33 PM - Followers: 97 - Board type: Free - Posts Today: 0

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.



BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013

“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky

Link To Interview with BioLineRX VP Of Business Development: -  BioLineRX Website

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference 03/14/2018 07:00:00 AM
BLRX News: Report of Foreign Issuer (6-k) 03/12/2018 07:02:33 AM
BLRX News: Annual and Transition Report (foreign Private Issuer) (20-f) 03/06/2018 07:08:50 AM
BLRX News: Report of Foreign Issuer (6-k) 03/06/2018 07:01:21 AM
BLRX News: BioLineRx Reports Year End 2017 Financial Results 03/06/2018 07:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1757  Sticky Note BioLineRx Ltd. (BLRX) BooDog 03/06/18 07:53:02 AM
#1759   It's one to keep an eye on till BooDog 03/06/18 02:13:33 PM
#1758   Only one analyst asked a question on today's Bickema 03/06/18 02:09:30 PM
#1757   BioLineRx Ltd. (BLRX) BooDog 03/06/18 07:53:02 AM
#1756   Everybody losing interest here? Tired of bouncing up GolfFishSurf 02/27/18 10:55:37 AM
#1755   Bvf Boosted Biolinerx LTD (BLRX) Holding by $8.50 xzy007 02/22/18 11:20:38 AM
#1754   I will laugh with you Dizzle96 02/18/18 02:08:38 PM
#1753   Positive news coming.... BollixMeArse 02/15/18 02:59:13 AM
#1752   Can't hang out too long in penny land Dizzle96 02/13/18 05:13:43 PM
#1751   #DEAD #BLRX Dizzle96 02/13/18 05:13:09 PM
#1750   Weird not much talk in this board lately. Prices Dizzle96 02/10/18 02:38:54 AM
#1749   I'm just grabbing these cheapies. Loading up at the Dizzle96 02/10/18 02:38:07 AM
#1748   Time to load up the wagons !! BLRX cheaper Dizzle96 02/05/18 08:01:44 PM
#1747   Palm is getting itchy. My .95 target BooDog 02/05/18 04:03:10 PM
#1746   Did you see the big cancer news in Amatuer17 02/04/18 03:59:44 PM
#1745   Maybe not that much but I'll be adding BooDog 02/04/18 02:44:41 PM
#1743   I'm up to 12,000 shares!!! They're getting Dizzle96 02/04/18 01:55:48 PM
#1742   If Amateur turns out to be right and BooDog 01/31/18 04:10:19 PM
#1741   I'm still pessimistic on this. Based on my Dizzle96 01/31/18 02:59:58 PM
#1740   Pleased to see a few writers covering BioLineRx. BooDog 01/30/18 10:58:21 AM
#1739   Yup and history will show what sham this Dizzle96 01/30/18 10:39:20 AM
#1738   thanks for posting, good read TAB78 01/30/18 08:10:10 AM
#1737   Agree - it is long term play but Amatuer17 01/29/18 07:42:17 PM
#1736   Hope this works BiolineRx Has Huge Upside In 2018 $BLRX http://www.seekingalpha. tsoprano-1 01/29/18 07:38:09 PM
#1735   Seeking Alpha article out on BLRX. Quite bullish tsoprano-1 01/29/18 07:27:55 PM
#1734   Will we get an update on Asco presentations Amatuer17 01/27/18 08:12:08 AM
#1733   All real people need to do is their BooDog 01/26/18 02:59:19 PM
#1732   Market is booming today!! Dow is up over Dizzle96 01/26/18 02:46:15 PM
#1731   Really I am not here as a dream Dizzle96 01/26/18 02:45:41 PM
#1730   Considering I've only started here, a relationship that BooDog 01/25/18 06:44:23 PM
#1729   LOOK at the 3 year chart and tell Dizzle96 01/25/18 06:37:03 PM
#1728   Nothing's holding up when you're in the red Dizzle96 01/25/18 06:34:39 PM
#1727   I think folks are starting to sniff this Dizzle96 01/25/18 06:33:56 PM
#1726   LOL you're catching on here buddy Dizzle96 01/25/18 06:32:38 PM
#1725   Like seeing those batch orders come in. BooDog 01/25/18 03:29:36 PM
#1724   I see a couple people are posting the Dizzle96 01/25/18 09:53:05 AM
#1723   Very interesting that a tiny company has 3-4 Amatuer17 01/23/18 08:28:20 AM
#1722   BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Amatuer17 01/23/18 08:25:14 AM
#1721   BioLineRx Reports Data at ASCO-SITC Conference Showing Complete BooDog 01/23/18 08:01:48 AM
#1720   I think you're about the .90 a share Dizzle96 01/22/18 09:51:59 AM
#1719   BLRX is down from $3 a share. Dizzle96 01/22/18 09:50:27 AM
#1718   Data on news and zero pop. Shocker lmfao Rogerthat1 01/21/18 10:27:53 PM
#1717   Shares of BioLineRx have outperformed the industry in a midastouch017 01/18/18 12:15:01 PM
#1716   Almost added on Tuesday watching for bottom, didn't BooDog 01/18/18 07:04:31 AM
#1715   Wow! Amazing day in the market today!! Just Dizzle96 01/17/18 05:48:43 PM
#1714   Oh my bad, there was GOOD news again. AND Dizzle96 01/17/18 03:18:54 PM
#1713   Ouch! LOL looks like another case of #BLRX Gotcha Dizzle96 01/17/18 03:16:08 PM
#1712   Agree - this is kind of new treatment Amatuer17 01/17/18 09:05:29 AM
#1711   That's great! Getting the T-Cell response is BooDog 01/17/18 08:34:33 AM
#1710   Did you see they have 4 presentations in ASCO Amatuer17 01/17/18 08:16:20 AM
#1709   Very promising. Heading to ASCO. BooDog 01/17/18 08:04:18 AM